# Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT

> **NCT05831098** · NA · COMPLETED · sponsor: **MedMira Laboratories Inc.** · enrollment: 600 (actual)

## Conditions studied

- Syphilis Infection
- Syphilis
- Early Syphilis, Symptomatic

## Interventions

- **DEVICE:** Reveal TP (Syphilis) Antibody Test

## Key facts

- **NCT ID:** NCT05831098
- **Lead sponsor:** MedMira Laboratories Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-12
- **Primary completion:** 2024-12-06
- **Final completion:** 2024-12-06
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2026-01-26

## Collaborators

- Public Health Agency of Canada (PHAC)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05831098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05831098, "Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05831098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*